Recent ultrasound data suggested a cumulative incidence at least 70%, uterine myoma originating from the myometrium of the uterus is the most common benign tumor in women with prevalence rates ranging from 20% to 40% are noted in different literatures though the incidence as per the histological diagnosis is much more than the clinical diagnosis which approximately 60% of women above 45 years of age are harboring myoma. Myoma is mostly asymptomatic. Size and location are the main factors that determine if a myoma leads to symptoms and problems. Important symptoms include abnormal uterine bleeding, abdominal discomfort, bloating, painful defecation, backache, urinary frequency or retention and infertility. It is associated with impairment of Health-Related Quality of Life. The presence of submucous and intramural myoma decreases fertility and its removal is beneficial. Patients have multiple options in the management of uterine myomas including observation, medical therapy, uterine artery embolization, high intensity focused ultrasound ablation and as well as surgical methods like Myomectomy and hysterectomy. Surgical removal is necessary when the myoma is symptomatic and resistant to medical management or interferes with reproduction. Although uterine artery embolization is now an effective way for managing symptomatic uterine myomas but its effect on future conception remains unclear.

On the basis of type, the market is segmented into abdominal, laparoscopic and hysteroscopic Myomectomy. The abdominal Myomectomy segment led the market in 2020. More commonly Myomectomy operation is performed by abdominal incision where the layered closure of uterus can be achieved easily; laparoscopic Myomectomy requires additional equipment’s whereas results of robotic Myomectomy are yet to be proved better than laparoscopic method, but in hysterectomy, blood transfusions, scar dehiscence in future pregnancy and many others has not yet been evaluated. Among available treatment modalities of which mostly in symptomatic myomas where open Myomectomy is the most likely treatment option despite of introduction of nonsurgical and newer methods available worldwide, where hemorrhagic complication that controlled by different techniques though individuals having drawbacks but the bilateral uterine arteries ligation not only very effective to minimize blood loss but also safe and no adverse effects on fertility and pregnancy.

North America accounted for the largest share of the global Myomectomy market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period.

With fibroids as the indication for surgery, 197,000 hysterectomies were performed in the United States in 2010, compared with approximately 40,000 myomectomies. Moreover, the rates of both laparoscopic and abdominal Myomectomy have decreased following the controversial morcellation advisory issued by the US Food and Drug Administration. The differences in the hysterectomy and Myomectomy rates might be explained by the many myths ascribed to Myomectomy. Such myths include the beliefs that Myomectomy, when compared with hysterectomy, is associated with greater risk of visceral injury, more blood loss, poor uterine healing, and high risk of fibroid recurrence, and that Myomectomy is unlikely to improve patient symptoms.